Tresiba and Lantus are both long-acting insulins used to manage blood sugar levels in people with type 1 or type 2 diabetes. (For more information on each’s drug uses, see the “What are Tresiba and ...

If you have diabetes, your doctor may prescribe Tresiba. Tresiba is a prescription drug that’s used to manage blood sugar levels. Tresiba is used in adults and some children to treat type 1 or type 2 ...

Tresiba (insulin degludec) and Lantus (insulin glargine) are brand-name prescription medications. They’re approved by the Food and Drug Administration (FDA) to treat type 1 and type 2 diabetes in ...

As with other drugs, Tresiba (insulin degludec) can cause side effects, such as headache, upper respiratory infection, and injection site reaction. If side effects of Tresiba become difficult to ...

Novo Nordisk today announced that the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opinions, recommending marketing authorisations, ...

Novo Nordisk, a global healthcare company, has launched Tresiba (insulin degludec) in Denmark for people with type 1 and type 2 diabetes. Tresiba is indicated for the treatment of diabetes mellitus in ...

Bagsværd, Denmark, 29 January 2016 - Novo Nordisk today announced the headline results from SWITCH 2, the first of two 2x32-weeks randomised, double-blind, cross-over, treat-to-target trials, ...

Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Tresiba® (insulin degludec) for the treatment of diabetes. Tresiba® is a new generation of once-daily ...